Zepbound vs Ozempic: Are They the Same? Key Differences

Zepbound and Ozempic are not the same drug, and they are not approved for the same thing. Zepbound is tirzepatide, made by Eli Lilly and approved for chronic weight management and for obstructive sleep apnea in adults with obesity. Ozempic is semaglutide, made by Novo Nordisk and approved for adults with type 2 diabetes, including lowering their cardiovascular and kidney risks. People compare them because both are weekly injections that reduce appetite and body weight, but it is a comparison across two different molecules and two different labels.

That makes this the trickiest pairing in the group. For weight loss in someone without diabetes, Zepbound is the on-label choice and has the stronger numbers. For type 2 diabetes, Ozempic is the on-label choice; Zepbound's diabetes-labeled twin is Mounjaro. The sections below sort out which facts apply to which reader.

Zepbound vs Ozempic: quick comparison

	Zepbound	Ozempic
Active ingredient	Tirzepatide	Semaglutide
Drug class	GIP and GLP-1 receptor agonist	GLP-1 receptor agonist
Maker	Eli Lilly	Novo Nordisk
FDA-approved for	Weight reduction and maintenance in adults with obesity, or overweight with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity	Blood sugar control in adults with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and cardiovascular disease; kidney protection in adults with type 2 diabetes and chronic kidney disease
Approved for weight loss?	Yes	No
Approved for type 2 diabetes?	No (Mounjaro is)	Yes
Weekly doses	2.5 mg starter; 5, 7.5, 10, 12.5, 15 mg	0.25 mg starter; 0.5, 1, 2 mg
Same ingredient sold as	Mounjaro	Wegovy; Rybelsus and Ozempic tablets (oral)
Manufacturer self-pay price per month	$299 to $449 with on-time refills	$199 to $499
Boxed warning	Thyroid C-cell tumors	Thyroid C-cell tumors

Is Zepbound the same as Ozempic?

No. Three common assumptions are worth correcting.

• "They're both GLP-1s." Ozempic is a GLP-1 receptor agonist. Zepbound activates the GLP-1 receptor and a second one, GIP. The FDA places tirzepatide in its own class. "GLP-1" has become shorthand for the whole group, the way a brand name sometimes stands in for a category, but GLP-1 is a hormone and a drug class, not a single medicine. Ozempic is one GLP-1 drug among several.
• "Zepbound is Lilly's Ozempic." Lilly's counterpart to Ozempic is Mounjaro, the diabetes brand of tirzepatide. Zepbound's counterpart at Novo Nordisk is Wegovy, the weight-management brand of semaglutide.
• "The pharmacy can swap them." It cannot. They are different molecules with unrelated dose scales. Changing from one to the other takes a new prescription and a dosing plan.

	Diabetes brand	Weight-management brand
Semaglutide (Novo Nordisk)	Ozempic	Wegovy
Tirzepatide (Eli Lilly)	Mounjaro	Zepbound

The like-for-like comparisons are Ozempic vs Mounjaro for diabetes and Wegovy vs Zepbound for weight. This page covers the diagonal.

Weight loss: tirzepatide vs Ozempic

No trial has compared Zepbound with Ozempic by brand. Two trials have compared their ingredients, and both favored tirzepatide.

Trial	Who was studied	Tirzepatide	Semaglutide
SURPASS-2, 40 weeks	1,879 adults with type 2 diabetes on metformin	-7.6 kg at 5 mg, -9.3 kg at 10 mg, -11.2 kg at 15 mg	-5.7 kg at 1 mg (an Ozempic dose)
SURMOUNT-5, 72 weeks	751 adults with obesity, no diabetes	-20.2% at 10 or 15 mg	-13.7% at 1.7 or 2.4 mg (Wegovy doses)

The second row matters for anyone comparing Zepbound with Ozempic for weight loss, because it understates the gap you would see with Ozempic. The semaglutide arm in SURMOUNT-5 used Wegovy doses of up to 2.4 mg. Ozempic's highest dose is 2 mg, and most people on it take 0.5 mg or 1 mg. In SUSTAIN FORTE, raising Ozempic from 1 mg to 2 mg added less than 1 kg of extra weight loss over 40 weeks in people with diabetes.

A study of U.S. electronic health records published in JAMA Internal Medicine in 2024 looked at 18,386 matched adults with overweight or obesity who started tirzepatide or semaglutide, predominantly the diabetes-labeled versions. Those on tirzepatide were about 1.8 times as likely to lose 5% of their weight, 2.5 times as likely to lose 10% and 3.2 times as likely to lose 15%. At 12 months the average difference was 6.9 percentage points. Rates of gastrointestinal side effects were similar.

Zepbound's own placebo-controlled trial, SURMOUNT-1, reported average weight loss of 15.0%, 19.5% and 20.9% at 5, 10 and 15 mg over 72 weeks in adults without diabetes, versus 3.1% on placebo. In adults with type 2 diabetes (SURMOUNT-2), the averages were 12.8% and 14.7% at 10 and 15 mg. All of these are group averages with diet and exercise counseling; some people lose far more and some far less.

If you have type 2 diabetes

This is where Ozempic has clear advantages on paper, even though tirzepatide lowers A1C more in head-to-head testing.

• Labeling. Ozempic is approved to treat type 2 diabetes. Zepbound is not; the label lists type 2 diabetes only as one of the weight-related conditions that can qualify an adult with overweight for treatment. If tirzepatide is the right drug for your diabetes, the prescription will normally be for Mounjaro.
• Heart. Ozempic lowered major cardiovascular events against placebo in SUSTAIN-6 (6.6% versus 8.9%) and carries that indication. Zepbound has no cardiovascular indication. Mounjaro gained one in August 2026 for adults with type 2 diabetes at high risk.
• Kidneys. In the FLOW trial, Ozempic 1 mg cut the risk of major kidney outcomes and cardiovascular death by 24% in people with type 2 diabetes and chronic kidney disease. No tirzepatide product has a kidney indication.
• Low blood sugar. With either drug, the risk rises if you also take insulin or a sulfonylurea. Doses of those medicines are often reduced when a GLP-1 drug is started.
• Eyes. Rapid improvement in blood sugar can temporarily worsen diabetic retinopathy. Both labels flag this; tell your eye doctor you are starting treatment.

If you do not have diabetes

Zepbound is approved for you if your BMI is 30 or higher, or 27 or higher with at least one weight-related condition. Ozempic is not approved for you at all; any prescription would be off-label, insurers are unlikely to pay, and the dose stops at 2 mg. The on-label semaglutide option is Wegovy.

Zepbound is also the only drug in this group approved for moderate to severe obstructive sleep apnea in adults with obesity, at maintenance doses of 10 or 15 mg. In the SURMOUNT-OSA trials, the number of breathing interruptions per hour dropped by roughly 25 to 29 with tirzepatide and about 5 with placebo after one year.

On the other hand, if you have established cardiovascular disease with overweight or obesity and no diabetes, semaglutide is the molecule with outcome evidence in that exact population: in SELECT, 6.5% of people on Wegovy 2.4 mg had a heart attack, stroke or cardiovascular death, versus 8.0% on placebo. That indication belongs to Wegovy, not Ozempic, and tirzepatide has not shown the same in people without diabetes.

Side effects of Zepbound vs Ozempic

The lists overlap heavily. The percentages do not line up neatly because Zepbound was studied at weight-management doses for 72 weeks and Ozempic at diabetes doses in shorter trials.

Side effect	Zepbound 5 / 10 / 15 mg	Ozempic 0.5 / 1 mg
Nausea	25% / 29% / 28%	15.8% / 20.3%
Diarrhea	19% / 21% / 23%	8.5% / 8.8%
Vomiting	8% / 11% / 13%	5% / 9.2%
Constipation	17% / 14% / 11%	5% / 3.1%
Abdominal pain	9% / 9% / 10%	7.3% / 5.7%
Injection-site reactions	6% / 8% / 8%	not in the common list
Hair loss	5% / 4% / 5%	not in the common list

When the two molecules were given to similar people in SURPASS-2, stomach side effects were close: nausea in 17% to 22% on tirzepatide and 18% on semaglutide 1 mg, diarrhea in 13% to 16% versus 12%, vomiting in 6% to 10% versus 8%.

Shared serious warnings. Thyroid C-cell tumors (boxed warning, based on rodent studies), pancreatitis, gallbladder disease, kidney injury from dehydration, severe gastrointestinal reactions, serious allergic reactions, and aspiration during anesthesia or deep sedation. Neither drug is for people with a personal or family history of medullary thyroid carcinoma or with MEN 2.

Differences that affect daily life.

• Zepbound can reduce the absorption of birth control pills. The label advises a non-oral method or a backup barrier method for four weeks after starting and after every dose increase. Ozempic has no such instruction.
• Ozempic's label says to stop the drug at least two months before a planned pregnancy. Zepbound's says to stop when pregnancy is recognized, noting that weight loss offers no benefit in pregnancy and may cause fetal harm.
• Semaglutide leaves the body more slowly (half-life about one week, versus about five days for tirzepatide), so side effects can take longer to fade after a dose.

Seek emergency care for severe abdominal pain that does not go away, or swelling of the face, lips or throat or trouble breathing. Call your prescriber about persistent vomiting or diarrhea, signs of dehydration, or changes in vision.

Dosing and devices

	Zepbound	Ozempic
Start	2.5 mg weekly for 4 weeks	0.25 mg weekly for 4 weeks
Next	5 mg; then 2.5 mg increases at least 4 weeks apart	0.5 mg; then 1 mg and 2 mg at least 4 weeks apart if needed
Maintenance	5, 10 or 15 mg (10 or 15 mg for sleep apnea)	0.5, 1 or 2 mg
Missed dose window	4 days	5 days
Minimum gap when changing injection day	3 days	2 days
Device	Single-dose auto-injector pen, vial with syringe, or four-dose KwikPen	Multi-dose dial pen with attachable needles
Out of the refrigerator	Single-dose pens and vials: up to 21 days at up to 86°F	In-use pen: up to 56 days at 59°F to 86°F

The milligram numbers are not comparable. Zepbound 5 mg is not "more" than Ozempic 2 mg in any direct sense; they are separate scales for separate molecules.

Tirzepatide vs Ozempic cost

Prices checked on the manufacturers' pages on October 14, 2026:

	Zepbound	Ozempic
List price	$1,086.37 a month for single-dose pens	$1,027.51 per pen
Self-pay starter	$299 (2.5 mg vial or KwikPen)	$199 a month for the first two fills of 0.25 or 0.5 mg (new patients, through December 31, 2026)
Self-pay ongoing	$399 (5 mg); $449 for 7.5 to 15 mg if refilled within 45 days, otherwise $499 (7.5 mg) or $699 (10 to 15 mg)	$349 for 0.25, 0.5 or 1 mg; $499 for 2 mg
With commercial coverage and savings card	As little as $25 per fill of single-dose pens	As little as $25 a month
Medicare	$50 copay for the KwikPen through the GLP-1 Bridge for eligible weight-management patients; possible Part D coverage for sleep apnea	Part D coverage for type 2 diabetes, cost set by the plan

Two worked examples for a cash payer over the first 12 fills (each fill covers four weeks):

• Ozempic, settling at 1 mg: two starter fills at $199, then ten fills at $349, about $3,888.
• Zepbound, settling at 10 mg: one fill at $299 (2.5 mg), two at $399 (5 mg), then nine at $449 with on-time refills, about $5,138. A person who climbs more slowly pays less in the early months.

Self-pay programs still require a valid prescription, and Lilly's terms tie Zepbound's self-pay price to its approved uses. Insurance changes the math entirely: a plan that covers Ozempic for diabetes may exclude Zepbound for weight. Every route is laid out in GLP-1 cost without insurance.

Three common situations

"I have type 2 diabetes, I'm on Ozempic 1 mg, and my weight has stalled."

Options your prescriber may raise include increasing Ozempic to 2 mg, or changing to tirzepatide. For diabetes, tirzepatide would be prescribed as Mounjaro, which insurance is more likely to cover than Zepbound. A modeling study by Lilly scientists predicted further A1C and weight reductions after switching from maintenance doses of semaglutide to tirzepatide 5 mg and above, but that is a simulation, not a trial.

"I don't have diabetes. My doctor prescribed Ozempic for weight and my plan denied it."

That is the expected result; Ozempic's label does not include weight management. Ask about Wegovy or Zepbound, check whether your plan covers either, and compare the manufacturers' self-pay prices if it covers neither.

"I'm on Zepbound and was just diagnosed with type 2 diabetes."

Tirzepatide treats both conditions. Your prescriber may keep you on Zepbound or move you to Mounjaro at the same dose for coverage reasons; see Mounjaro vs Zepbound. A change to Ozempic would only make sense for a specific reason, such as kidney disease or a formulary rule.

Switching from Ozempic to Zepbound

There is no FDA conversion chart between semaglutide and tirzepatide, and none between these two brands. Published guidance for swapping weekly drugs in this class says to give the first dose of the new one 7 days after the last dose of the old one, and to treat any equivalence table as a starting point only. Many prescribers begin tirzepatide at 2.5 mg or 5 mg even in people who were on a full Ozempic dose, then step up every four weeks. A suggested comparison chart from a 2023 pharmacy report, and the questions to ask before you switch, are in switching from Ozempic to Mounjaro, which applies equally to Zepbound because the tirzepatide doses are identical.

Never take the two together. Zepbound's label states that combining it with any GLP-1 receptor agonist is not recommended.

How to decide

1. Name the main condition. Type 2 diabetes points to Ozempic or Mounjaro. Weight management without diabetes points to Zepbound or Wegovy. Sleep apnea with obesity points to Zepbound.
2. Check for kidney or heart disease. These favor a drug with the matching indication.
3. Look up your formulary. Coverage often narrows the field to one.
4. Review your other medicines. Birth control pills, insulin and sulfonylureas all change the conversation.
5. Price the maintenance dose for a full year, not the starter month.
6. Agree on a follow-up point to judge whether the drug is working and tolerable.

For a ranking of every approved option by average weight loss, see the best GLP-1 for weight loss; for the science of the two molecules, semaglutide vs tirzepatide.